Summary & Overview
HCPCS M0222: Intravenous Injection of Bebtelovimab, Includes Monitoring
HCPCS Level II code M0222 denotes the intravenous injection of bebtelovimab and includes medication administration plus post-administration monitoring. This code captures a single-service encounter for delivery of a monoclonal antibody and the immediate observation period that follows, reflecting how payers identify and reimburse outpatient biologic injections. Nationally, accurate use of M0222 affects clinical documentation, claims processing, and reporting for COVID-19 targeted therapies and other monoclonal antibody treatments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing benchmarks where available, and relevant policy considerations impacting access and payment for monoclonal antibody injections administered in outpatient infusion settings.
Readers will learn the clinical and billing context for M0222, typical sites of service for administration, common billing modifiers supplied in input, and where to find related billing references. The summary also signals areas where input data was not provided and where readers should seek payer-specific policies or client-specific fee schedules for reimbursement details.
Billing Code Overview
HCPCS Level II code M0222 represents intravenous injection of bebtelovimab, including the medication administration and post-administration monitoring. The service type is an intravenous monoclonal antibody infusion/injection. The typical site of service is an outpatient infusion clinic, emergency department, or other outpatient facility where intravenous biologic therapies are administered and monitoring is available.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with laboratory-confirmed high-risk SARS-CoV-2 infection who meets eligibility for monoclonal antibody therapy to reduce progression to severe COVID-19. The patient presents to an outpatient infusion center, emergency department observation unit, or hospital outpatient infusion clinic. After initial evaluation by a licensed clinician (history, vital signs, oxygen saturation, review of symptoms and contraindications), informed consent is obtained for intravenous monoclonal antibody therapy. An order is placed for M0222 (intravenous injection, bebtelovimab), and nursing staff prepare the medication in accordance with institutional protocols. The procedure includes intravenous administration of bebtelovimab, continuous monitoring during infusion for infusion-related or hypersensitivity reactions, and a post-administration observation period (typically 30–60 minutes) with vital signs documented. If an adverse reaction occurs, infusion is slowed or stopped and emergency interventions are initiated per protocol. After completion of monitoring without significant events, discharge instructions are provided and documentation includes indication, time of start and finish, lot numbers, amount administered, and post-administration assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to administer is substantially greater than typically required (document rationale). |